Kyntra Bio reports $12 million Q2 2026 net income
Kyntra Bio reports $12 million in net income for Q2 2026, versus a $13.7 million net loss a year earlier, while FG3246, FG3180 and roxadustat programs advance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Kyntra Bio (KYNB) reports Q2 2026 results and business update
Kyntra Bio (KYNB) reports Second Quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.